Samantha Truex

CEO-in-Residence, CEO of Oblenio Bio

2025

Aditum Bio is a biotech venture capital firm blending venture creation with a dedicated translational, clinical and manufacturing team to rapidly translate scientific discoveries into innovative new medicines. I serve as CEO of portfolio company Oblenio Bio and as CEO advisor to other portfolio companies.

Board Member, Chair of Nom & Gov Committee

2024

Chair of the Board of Directors, Compensation Committee Chair

2022

Chief Executive Officer

2021 - 2024

Founding CEO and first employee of Upstream Bio. Built experienced development organization; initiated and completed multiple clinical studies, including Phase 1b and Japan ethno-bridging study; raised $200M Series B at attractive step-up based on compelling Phase 1b data, even during tough market of 2023. Prioritized indications and started two global Phase 2 studies in Q1 2024. Led team through SVB crisis and other corporate challenges. Set company and strategy for highly successful IPO 6 months after my departure.

Member of the Board; Chair of Audit Committee

2018 - 2022

Inspired by nature, HotSpot Therapeutics is moving beyond active site inhibition to allosterically target drivers of protein function and deliver first-in-class medicines with exceptional properties.

CEO

2018 - 2021

Quench Bio sought to discover inhibitors of gasdermin, a novel target that plays a key role in inflammatory cell death. We aimed to provide effective therapies for patients with severe inflammatory diseases. Quench Bio raised a $50M Series A funded by Atlas Venture, RA Capital, Arix Bioscience and AbbVie Ventures. After almost 3 years of attempts to drug this interesting target, we wound down Quench and returned capital to the investors.

COO and Head of Corporate Development

2016 - 2017

Led Corporate Development activities, including corporate/financing strategy, partnering, legal and operational alliances across manufacturing, research and development. Drove evaluation of financing options and executed on competitive reverse merger process culminating in signing of merger with Mirna in May 2017.

Chief Business Officer

2014 - 2016

Padlock Therapeutics was acquired by Bristol-Myers Squibb (BMS) in 2016. Padlock Therapeutics was a venture-funded biotech company focused on developing therapeutic inhibitors of a family of enzymes called protein-arginine deiminases (PADs).

VP Corporate Development

2013 - 2014

VP, Program Executive for Fampyra

2012 - 2013

Vice President, Business Development

2010 - 2012

Sr. Director, Head of Product and Commercial Development for Hemophilia

2008 - 2010

Sr. Director, Corporate Development

2006 - 2008

Head of Mergers and Acquisitions for Biogen Idec. Led M&A strategy/evaluations and interactions with investment bankers. Led acquisition of Syntonix in January 2007 and was instrumental in Biogen Idec sale process in Q4 2007.

Director, Business Development

1998 - 2006